Dihydroergotamine


Generic Medicine Info
Administration
May be taken with or without food.
Contraindications
Ischaemic heart disease (i.e. angina pectoris, silent ischaemia, history of MI), coronary artery vasospasm (e.g. Prinzmetal's variant angina), vasospastic coronary artery disease, uncontrolled HTN, haemiplegic or basilar migraine, peripheral vascular disease, sepsis. Patient following vascular surgery. Concomitant use w/ potent CYP3A4 inhibitors. Severe hepatic or renal impairment. Pregnancy and lactation.
Special Precautions
Patients w/ risk factors predictive of coronary artery disease (e.g. HTN, hypercholesterolemia, angina), history of drug induced fibrotic disorders, severe orthostatic hypotension. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor CV status prior to and periodically during therapy.
Adverse Reactions
Significant: Nausea, vomiting. Rarely, pleural, retroperitoneal, and cardiac valvular fibrosis, increase in BP. Nervous: Paraesthesia, numbness of fingers and toes, tingling sensation, dizziness, headache. CV: HTN, vasospasm. GI: Abdominal pain, diarrhoea, taste disturbance, throat irritation. Resp: Dyspnoea, nasal irritation. Muscoloskeletal: Muscle spasm. Dermatologic: Facial oedema, urticaria, rash, increased sweating.
Potentially Fatal: Rarely, coronary artery vasospasm, transient myocardial ischaemia, acute MI, ventricular tachycardia, ventricular fibrillation, cerebrovascular events (e.g. cerebral or subarachnoid haemorrhage, stroke), gangrene.
Drug Interactions
Enhanced vasoconstriction w/ other ergot alkaloids, sumatriptan, β-blockers, nicotine, and other vasoconstrictors. May lead to serotonin-like syndrome (e.g. weakness, incoordination, hyperreflexia) when used w/ SSRIs.
ATC Classification
N02CA01 - dihydroergotamine ; Belongs to the class of ergot alkaloids preparations. Used to relieve migraine.
Disclaimer: This information is independently developed by CIMS based on dihydroergotamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in